Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

Group 1 - Regenxbio reported a quarterly loss of $1.01 per share, better than the Zacks Consensus Estimate of a loss of $1.27, and an improvement from a loss of $1.43 per share a year ago, resulting in an earnings surprise of 20.47% [1] - The company posted revenues of $21.21 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 7.36%, and down from $22.21 million in the same quarter last year [2] - Over the last four quarters, Regenxbio has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Group 2 - The stock has underperformed the market, losing about 13.7% since the beginning of the year compared to the S&P 500's decline of 4.8% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The trend for estimate revisions for Regenxbio is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Group 3 - The current consensus EPS estimate for the upcoming quarter is -$1.08 on revenues of $20.36 million, and for the current fiscal year, it is -$1.52 on revenues of $274.95 million [7] - The Medical - Biomedical and Genetics industry, to which Regenxbio belongs, is currently in the top 26% of Zacks industries, suggesting a positive outlook for the sector [8]